|1.||Wuisman, Paul I J M: 2 articles (12/2005 - 12/2004)|
|2.||Stallmann, Hein P: 2 articles (12/2005 - 12/2004)|
|3.||Lyaruu, D M: 2 articles (12/2004 - 06/2003)|
|4.||Brouwer, Carlo P J M: 1 article (12/2005)|
|5.||Faber, Chris: 1 article (12/2005)|
|6.||de Blieck-Hogervorst, Jolanda M A: 1 article (12/2005)|
|7.||Amerongen, Arie V Nieuw: 1 article (12/2005)|
|8.||Bronckers, Antonius L J J: 1 article (12/2005)|
|9.||Hoogendoorn, Roel J W: 1 article (12/2004)|
|10.||Faber, Christopher: 1 article (12/2004)|
12/01/2004 - "The aim of the study was to investigate the efficacy of the antimicrobial peptide Dhvar-5 in a prophylactic, methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. "
12/01/2004 - "In vivo comparison of Dhvar-5 and gentamicin in an MRSA osteomyelitis prevention model."
06/01/2003 - "In order to develop a new local treatment using Dhvar-5 for osteomyelitis, we investigated its release from PMMA beads and its antimicrobial activity against a clinical isolate of methicillin-resistant Staphylococcus aureus (MRSA) before and after release from PMMA beads. "
12/01/2005 - "Both hLF1-11 and Dhvar-5 dose-dependently killed all bacterial strains, starting at concentrations of 6 microg/mL. hLF1-11 had no effect on mammalian cells at concentrations up to 400 microg/mL, but Dhvar-5 induced significant hemolysis (37% at 200 microg/mL) and bone cell death (70% at 400 microg/mL). "
|2.||Polymethyl Methacrylate (Sol)